Business Context and Reporting Period
Perspective Therapeutics, Inc. (CATX) is a radiopharmaceutical development company focused on alpha-emitting isotope Lead-212 (212Pb) therapies for cancer. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company is classified as a non-accelerated filer and a smaller reporting company. As of August 5, 2026, there were 114,151,663 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Grant Revenue | $157,000 | $632,000 |
| Net Loss | $(52,975,000) | $(39,662,000) |
| Operating Loss | $(57,539,000) | $(45,871,000) |
| Research & Development Expenses | $42,916,000 | $30,952,000 |
| General & Administrative Expenses | $14,780,000 | $15,551,000 |
| Cash, Cash Equivalents & Short-Term Investments | $236,876,000 | $141,556,000 (Dec 31, 2025) |
| Net Cash Used in Operating Activities | $(52,118,000) | $(41,535,000) |
| Net Cash Provided by Financing Activities | $164,511,000 | $10,105,000 |
| Accumulated Deficit | $(387,815,000) | $(334,840,000) |
Material Changes vs. Prior Period
- Revenue Decline: Grant revenue decreased by $475,000 (75%) compared to the prior six-month period, reflecting reduced NIH funding recognition.
- Increased Operating Loss: Net loss increased by $13.3 million, driven primarily by a $12.0 million increase in R&D expenses due to expanded clinical trials, headcount, and manufacturing activities.
- Capital Raise: In February 2026, the Company completed a registered offering raising approximately $175.0 million in gross proceeds, significantly boosting liquidity.
- Investing Outflows: Net cash used in investing activities surged to $94.5 million (from $1.3 million), primarily due to $186.0 million in purchases of available-for-sale securities and $21.1 million in property and equipment additions.
- Share Count: Weighted average shares outstanding increased significantly due to the 2026 offering, resulting in a lower loss per share ($0.47) compared to the prior year ($0.54) despite higher absolute losses.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash resources of $236.9 million are sufficient to fund operations into late 2027. However, the Company expects expenses to increase significantly as it advances clinical assets and expands manufacturing.
- Clinical Progress:
- VMT-α-NET (Neuroendocrine Tumors): Cohort 3 (6.0 mCi) is fully enrolled; Cohort 4 (front-loading dose) initiated. European Commission granted orphan designation in July 2026. Phase 3 study design is being finalized with regulatory engagement ongoing.
- VMT01 (Melanoma): Combination therapy with nivolumab is underway. Updated data showed 86% of patients in the 3.0 mCi monotherapy cohort experienced stable disease or partial response.
- PSV359 (Solid Tumors): Cohort 3 (6.0 mCi) fully enrolled. First patient treated in May 2026.
- Manufacturing Expansion: The Company is modifying facilities in Chicago and Los Angeles (completion expected 2027) and upgrading the Somerset, NJ facility for Phase 3 capacity. A "take-or-pay" agreement with the U.S. Department of Energy commits the Company to purchasing approximately $9.9 million of Thorium-228.
- Risks: Key risks include the failure of clinical trials to demonstrate efficacy, delays in regulatory approval, the need for additional capital before profitability, and potential supply chain disruptions for isotopes. The Company has no commercial product revenue.
Investor Verification Checklist
- Verify the sufficiency of the $236.9 million cash balance against the projected burn rate for clinical trials and facility construction through late 2027.
- Monitor the timeline and results of the Phase 3 study design for VMT-α-NET, specifically regulatory feedback expected by year-end 2026.
- Assess the impact of the $9.9 million "take-or-pay" DOE commitment on future cash flows if clinical demand does not materialize.
- Review the dilution impact of the 2026 offering and the remaining capacity under the $250 million ATM agreement.
- Track the enrollment and safety data for the new meningioma cohort (LEMONαDE) and the combination therapy cohorts for VMT01.